EP Patent

EP0563813B1 — Transdermal compositions

Assigned to Aventis Pharmaceuticals Inc · Expires 1999-12-01 · 26y expired

What this patent protects

Novel compositions comprising an antiandrogenic compound of the formula <CHEM> wherein R is COR1 wherein R1 is loweralkyl and a vehicle comprising a metabolism modulator and a polar organic solvent, are disclosed.

USPTO Abstract

Novel compositions comprising an antiandrogenic compound of the formula <CHEM> wherein R is COR1 wherein R1 is loweralkyl and a vehicle comprising a metabolism modulator and a polar organic solvent, are disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
EP0563813B1
Jurisdiction
EP
Classification
—
Expires
1999-12-01
Drug substance claim
No
Drug product claim
No
Assignee
Aventis Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.